Amphastar ( AMPH ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025 at 9:00 p.m. ETChief Executive Officer - Dan DischnerContinue reading ...
Pulmatrix ( PULM ) Q2 Revenue Falls 100%
Pulmatrix ( NASDAQ:PULM ) , a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025.
MannKind ( MNKD ) Q2 Revenue Rises 6%
MannKind ( NASDAQ:MNKD ) , a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from this release was a 6% increase in total revenue to $76.53 million ( GAAP ) , primarily from ...
MannKind ( MNKD ) Reports Break-Even Earnings for Q2
MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement - MannKind ( NASDAQ:MNKD )
Strengthens MannKind's capital structure with flexible, long-term, non-dilutive funding MannKind to receive $75 million in cash at closing
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
• MannKind to receive $75 million in cash at closing
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
• Advanced pipeline: • MNKD-201: Plan to initiate Phase 2 clinical trial for IPF by YE 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) today reported financial results for the second quarter 2025 and provided a business ...
AbCellera Biologics Inc. ( ABCL ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ABCELLERA BIOLG (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate MannKind ( MNKD ) to Report a Decline in Earnings: What to Look Out for
MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amarin ( AMRN ) Soars 27.3%: Is Further Upside Left in the Stock?
Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Top 3 Health Care Stocks That May Rocket Higher This Quarter - INVO Fertility ( NASDAQ:IVF ) , MannKind ( NASDAQ:MNKD )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin ( Afrezza® ) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23 - MannKind ( NASDAQ:MNKD )
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation MNKD, a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled ...
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin ( Afrezza® ) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Session ...
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
Only known U.S. pro racing driver competing full-time with Type 1 diabetes will share an inspirational message to kick off Chevrolet Detroit Grand Prix week Only known U.S. pro racing driver competing full-time with Type 1 diabetes will share an inspirational message to kick off Chevrolet ...
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29 - MannKind ( NASDAQ:MNKD )
WESTLAKE VILLAGE, Calif., May 27, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation MNKD will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes ( T1D ) for a one-of-a-kind experience with Detroit area youth and families during the week of the Chevrolet Detroit ...
MannKind ( MNKD ) Beats Q1 Earnings and Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 33.33% and 5.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Conference call to provide corporate updates today at 9:00 am ET ...
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Conference call to provide corporate updates today at 9:00 am ET • Advanced pipeline: • Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025 • MNKD-201: Expect to continue to next phase of global development in 2H 2025
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Ligand Pharmaceuticals ( NASDAQ:LGND ) , MannKind ( NASDAQ:MNKD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B of A Securities analyst Joshua Dennerlein initiated coverage on MSCI Inc.
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 - MannKind ( NASDAQ:MNKD )
Five presentations affirm positive outcomes utilizing inhaled insulin An sNDA filing for Afrezza in pediatric population anticipated in 2025
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March ...
MannKind ( MNKD ) Q4 2024 Earnings Call Transcript
MNKD earnings call for the period ending December 31, 2024.
MannKind ( MNKD ) Q4 Earnings Meet Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 0% and 1.48%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Unveiling MannKind ( MNKD ) Q4 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of MannKind (MNKD) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Roivant Sciences Ltd. ( ROIV ) Reports Q3 Loss, Tops Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 45.83% and 42.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
MannKind Expands Executive Leadership Team - MannKind ( NASDAQ:MNKD )
Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025
MannKind Expands Executive Leadership Team
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) , a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, ...
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash - MannKind ( NASDAQ:MNKD )
Cash position after closing will be in excess of $180 million DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- MannKind Corporation MNKD today announced today that it has entered into separate, privately negotiated exchange agreements with certain holders ( the ...
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
• Cash position after closing will be in excess of $180 million
MannKind Shares Are falling Today: What's Going On? - MannKind ( NASDAQ:MNKD )
MannKind Corporation MNKD are trading lower Monday. The company released its six-month results from its Phase 3 INHALE-1 pediatric diabetes trial. Here's what you need to know. What To Know: The trial investigated the use of Afrezza ( insulin human ) Inhalation Powder in children and adolescents ...
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin ( Afrezza® ) - MannKind ( NASDAQ:MNKD )
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. ( ET ) to discuss company's diabetes program progression
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin ( Afrezza® )
MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN ...
CDSCO Approves Afrezza® ( insulin human ) Inhalation Powder in India - MannKind ( NASDAQ:MNKD )
India has the 2nd highest burden of diabetes worldwide CDSCO decision follows existing approvals in the U.S.A. and Brazil MannKind expects to ship product for Cipla Ltd. by end of 2025
CDSCO Approves Afrezza® ( insulin human ) Inhalation Powder in India
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India ...
MannKind ( MNKD ) Q3 2024 Earnings Call Transcript
MNKD earnings call for the period ending September 30, 2024.
MannKind ( MNKD ) Matches Q3 Earnings Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 0% and 9.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update - MannKind ( NASDAQ:MNKD )
MNKD-101 Phase 3 clinical trial expands globally MNKD-201 Phase 1 successfully completed; Plan to meet with FDA in 1H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 ( GLOBE NEWSWIRE ) -- MannKind Corporation MNKD today reported financial results for the quarter ended September ...
MannKind to Present at 2024 UBS Healthcare Conference - MannKind ( NASDAQ:MNKD )
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2024 ( GLOBE NEWSWIRE ) -- MannKind Corporation MNKD, a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that ...
MannKind to Present at 2024 UBS Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2024 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, ...
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases - MannKind ( NASDAQ:MNKD )
Met primary objective demonstrating nintedanib DPI was safe and well tolerated Participants did not experience adverse events typically reported with oral nintedanib Expect to meet with the FDA in 1H 2025 to advance MNKD-201 into the next phase of development
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
• Met primary objective demonstrating nintedanib DPI was safe and well tolerated • Participants did not experience adverse events typically reported with oral nintedanib • Expect to meet with the FDA in 1H 2025 to advance MNKD-201 into the next phase of development
MannKind Corporation ( MNKD ) Hits Fresh High: Is There Still Room to Run?
MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial ( NTM ) Lung Disease
First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of NTM Lung Disease ...
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why MannKind ( MNKD ) Could Beat Earnings Estimates Again
MannKind (MNKD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MannKind ( MNKD ) Just Overtook the 20-Day Moving Average
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
More Adults With Type 1 Diabetes Achieved A1C Goal ( <7% ) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin ( Afrezza® ) - MannKind ( NASDAQ:MNKD )
30-week results from the Phase 4 INHALE-3 study expand upon the positive 17-week data presented earlier this year at the American Diabetes Association's 84th Scientific Sessions Switching to, or remaining on Afrezza allowed twice as many people to get to goal during the extension phase
More Adults With Type 1 Diabetes Achieved A1C Goal ( <7% ) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin ( Afrezza® )
MORE ADULTS WITH TYPE 1 DIABETES ACHIEVED A1C GOAL (<7%) AFTER SWITCHING FROM MULTIPLE DAILY INSULIN INJECTIONS OR AUTOMATED PUMPS TO INHALED INSULIN ...
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial ( ICoN-1 ) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial ( NTM ) Lung Disease - MannKind ( NASDAQ:MNKD )
Clearance to proceed also received from health authorities in South Korea and Australia, with Taiwan expected in 4Q 2024
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial ( ICoN-1 ) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial ( NTM ) Lung Disease
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment ...
